VivoSeq
Immunology

Psoriatic Arthritis

101

Pipeline Programs↗

40

Active Trials↗

47

Companies Involved↗

Psoriatic Arthritis is a highly competitive landscape with 101 programs across 47 companies. The most active players are Roche, Enlivex Therapeutics Ltd., selectION Therapeutics GmbH. 18 therapies are approved with 27 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

72/100

Pipeline Velocity

41/100

Mech. Concentration

13/100

Completion Rate

84/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

3 programs

Phase 1E

Enlivex Therapeutics Ltd.

1 program

Phase 1S

selectION Therapeutics GmbH

1 program

Phase 1GSK logo

GSK

1 program

Phase 1H

Hikma Pharmaceuticals LLC

1 program

Phase 1D

Dexcel Pharma Technologies Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

78 of 102 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody1818%Protein / enzyme33%Peptide33%

Small molecule leads; the ring shows all 102 classified programs, each share of the total. Modality classified for 97% of 115 pipeline programs.

Analysis

Trial Status

198

clinical trials

Completed125 · 63%
Recruiting18 · 9%
Terminated14 · 7%
Active, not recruiting12 · 6%
Unknown status10 · 5%
Withdrawn9 · 5%
Other10 · 5%

Clinical Trials

Trial Activity

198 trials

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Recruiting·CCARE ARTHRITIS LTD.·Phase 4·NCT06454188·100 enrolled
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
Recruiting·TTaichung Veterans General Hospital·Phase 4·NCT07149792·50 enrolled
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Recruiting·Amgen logoAmgen·Phase 3·NCT05767047·48 enrolled
A Study of Picankibart in Patients With Active Psoriatic Arthritis
Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 2/3·NCT07295509·222 enrolled
Preventing Structural Damage in Early Psoriatic Arthritis
Recruiting·—·Phase 4·NCT07486843·108 enrolled
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
Recruiting·AbbVie logoAbbVie·Phase 2·NCT06865105·120 enrolled
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Recruiting·Eli Lilly logoEli Lilly·Phase 4·NCT06864026·200 enrolled
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Recruiting·Takeda logoTakeda·Phase 3·NCT07286058·1,182 enrolled
Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis
Recruiting·EEnlivex Therapeutics Ltd.·Phase 1·NCT06522035·6 enrolled
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
Recruiting·HHansoh BioMedical R&D Company·Phase 2·NCT06176508·160 enrolled
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient
Recruiting·SSouth Valley University·N/A·NCT06870500·50 enrolled
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Recruiting·Amgen logoAmgen·Phase 3·NCT04804553·60 enrolled
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic Arthritis
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06640257·200 enrolled
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
Recruiting·IInventisBio Co., Ltd·Phase 2·NCT07315061·222 enrolled
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
Recruiting·UCB logoUCB·Phase 1·NCT07290036·392 enrolled
Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)